Mar 30th, 2026
Innovent Biologics Bullish on China Obesity Drug Outlook
Innovent Biologics has reported its first profit even as competition from weight-loss generics looms. Speaking exclusively to Bloomberg's "The China Show," CFO Rachel You says China's obesity drug market has massive potential and could mirror current penetration rates in the US.
